Imbesi S, Allegra A, Calapai G, Musolino C, Gangemi S
Department of Clinical and Experimental Medicine, School and Unit of Allergy and Clinical Immunology, University of Messina, Italy.
Division of Hematology, University of Messina, Italy.
Allergol Immunopathol (Madr). 2015 Jan-Feb;43(1):88-91. doi: 10.1016/j.aller.2013.07.005. Epub 2013 Oct 25.
Lenalidomide is an immunomodulatory drug (IMiD) used principally in the treatment of multiple myeloma (MM), myelodysplastic syndromes (MS) and amyloidosis. Adverse reactions related to lenalidomide include myelosuppression (mainly neutropenia but also thrombocytopenia), gastrointestinal problems, skin eruption, atrial fibrillation and asthenia, decreased peripheral blood stem cell yield during stem cell collection, venous thromboembolism, and secondary malignances. In this review we focused our attention on the cutaneous adverse reactions to lenalidomide.
来那度胺是一种免疫调节药物（IMiD），主要用于治疗多发性骨髓瘤（MM）、骨髓增生异常综合征（MS）和淀粉样变性。与来那度胺相关的不良反应包括骨髓抑制（主要是中性粒细胞减少，也包括血小板减少）、胃肠道问题、皮疹、心房颤动和乏力、干细胞采集期间外周血干细胞产量降低、静脉血栓栓塞以及继发性恶性肿瘤。在本综述中，我们将注意力集中于来那度胺的皮肤不良反应。
